

A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS

(Alphabetisch nach Erstautor sortiert)

1. **AMANN M, PEZOLD S, NAEGELIN Y, FUNDANA K, ANDELOVA M, WEIER K, STIPPICH C, KAPPOS L, RADUE EW, CATTIN P, SPRENGER T**
Reliable volumetry of the cervical spinal cord in MS Patient follow-up data with Cord Image Analyzer (*Cordia*)
J Neurol 2016; 263(7): 1364-1374. IF: 3.408
2. **ARRAMBIDE G, ESPEJO C, EIXARCH H, VILLAR L, ALVAREZ-CERMEÑO J, PICÓN C, KUHLE J, DISANTO G, KAPPOS L, SASTRE-GARRIGA J, PARETO D, SIMON E, COMABELLA M, RÍO J, NOS C, TUR C, CASTILLÓ J, VIDAL-JORDANA A, GALÁN I, ARÉVALO MJ, AUGER C, ROVIRAA, MONTALBAN X, TINTORE M**
Neurofilament light chain level is a weak risk factor for the development of MS
Neurology 2016; 87(11):1076-84 IF: 8.166
3. **ATHANASOPOULOU IM*, RASENACK M*, GRIMM C, AXER H, SINNREICH M, DÉCARD BF, GRIMM A** (*contributed equally)
Ultrasound of the nerves - An appropriate addition to nerve conduction studies to differentiate paraproteinemic neuropathies.
J Neurol Sci. 2016; 362:188-95. IF: 2.126
4. **BACIOGLU M, MAIA LF, PREISCHE O, SCHELLE J, APEL A, KAESER SA, SCHWEIGHAUSER M, ENINGER T, LAMBERT M, PILOTTO A, SHIMSHEK DR, NEUMANN U, KAHLE PJ, STAUFENBIEL M, NEUMANN M, MAETZLER W, KUHLE J*, JUCKER M*** (*equal contribution)
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
Neuron 2016; 91(1): 56-66. IF: 13.974
5. **BERNARDINI LR, ZECCA C, CLERICI VT, GOBBI C, MANTEGAZZA R, ROSSI S**
Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis
J Neurol Sci 2016; 369: 139-140. IF: 2.126
6. **BLAABJERG M, RUPRECHT K, SINNECKER T, KONDZIELLA D, NIENDORF T, KERRN-JESPERSEN BM, LINDELOF M, LASSMANN H, KRISTENSEN BW, PAUL F, ILLES Z**
Widespread inflammation in CLIPPERS syndrome indicated by autopsy and ultra-high-field 7T MRI
Neurol Neuroimmunol Neuroinflamm 2016;3:e226. IF: -
7. **BLOEHLIGER M, CESCHI A, RÜEGG S, JICK SS, MEIER CR, BODMER M**
Lifestyle factors, psychiatric and neurologic comorbidities, and drug use associated with incident seizures among adult patients with depression: a population-based nested case-control study
Eur J Epidemiol 2016; 31(11):1113-1122. IF: 7.105
8. **CALLEGARI I, MATTEI C, BENASSI F, KRUEGER F, GRAFMAN J, YALDIZLI Ö, SASSOS D, MASSUCCO D, SCIALÒ C, NOBILI F, SERRATI C, AMORE M, COCITO L, EMBERTI GIALLORETI L, PARDINI M**
Agomelatine Improves Apathy in Frontotemporal Dementia
Neurodegener Dis 2016; 16(5-6):352-6. IF: 2.937
9. **CASTETS P, FRANK S, SINNREICH M, RÜEGG MA**
"Get the Balance Right": Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders.
J Neuromuscul Dis 2016;3(2):127-155. IF: -
10. **CHENG YC, STANNE TM, GIESE AK, HO WK, TRAYLOR M, AMOUYEL P, HOLLIDAY EG, MALIK R, XU H, KITTNER SJ, COLE JW, O'CONNELL JR, DANESH J, RASHEED A, ZHAO W, ENGELTER S, GROND-GINSBACH C, KAMATANI Y, LATHROP M, LEYS D, THIJS V, METSO TM, TATLISUMAK T, PEZZINI A, PARATI EA, NORRVING B, BEVAN S, ROTHWELL PM, SUDLOW C, SLOWIK A, LINDGREN A, WALTERS MR, JANNES J, SHEN J, CROSSLIN D, DOHENY K, LAURIE CC, KANSE SM, BIS JC, FORNAGE M, MOKLEY TH, HOPEWELL JC, STRAUCH K, MULLER-NURASYID M, GIEGER C, WALDENBERGER M, PETERS A, MEISINGER C, IKRAM MA, LONGSTRETH WT, JR., MESCHIA JF, SESHADRI S, SHARMA P, WORRALL B, JERN C, LEVI C, DICHGANS M, BONCORAGLIO GB, MARKUS HS, DEBETTE S, ROLFS A, SALEHEEN D, MITCHELL BD**
Genome-Wide Association Analysis of Young Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2
Stroke 2016; 47(2):307-16. IF: 5.787
11. **CHIU I, PIGUET O, DIEHL-SCHMID J, RIEDL L, BECK J, LEYHE T, HOLSBOER-TRACHSLER E, BERRES M, MONSCH AU, SOLLBERGER M**
Dissociation in Rating Negative Facial Emotions between Behavioral Variant Frontotemporal Dementia and Major Depressive Disorder.
Am J Geriatr Psychiatry 2016;24(11):1017-1027. IF: 3.130
12. **CHAWLA S, KISTER I, WUERFEL J, BRISSET JC, LIU S, SINNECKER T, DUSEK P, HAACKE EM, PAUL F, GE Y**
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI
Am J Neuroradiol 2016; 37:1223-1230. IF: 3.124
13. **COHEN JA, KHATRI B, BARKHOF F, COMI G, HARTUNG HP, MONTALBAN X, PELLETIER J, STITES T, RITTER S, VON ROSENSTIEL P, TOMIC D, KAPPOS L** on behalf of the TRANSFORMS (trial assessing injectable interferon vs. FTY720 oral in RRMS) study group
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study
J Neurol Neurosurg Psychiatry 2016; 87(5):468-75. IF: 6.431
14. **COLLINS C, IVRY B, BOWEN JD, CHENG EM, DOBSON R, GOODIN DS, LECHNER-SCOTT J, KAPPOS L, GALEA I**

A comparative analysis of Patient-Reported Expanded Disability Status Scale tools
Mult Scler J 2016; 22(10):1349-58. IF: 4.671

15. **COMI G, FREEDMAN M, KAPPOS L, OLSSON T, MILLER A, WOLINSKY J, O'CONNOR P, BENAMOR M, DUKOVIC D, TRUFFINET P, LEIST T**
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Mult Scler Relat Disord 2016; (5): 97-104. IF: 1.150
16. **COMI G, DE STEFANO N, FREEDMAN MS, BARKHOF F, UITDEHAAG BMJ, DE VOS M, MARHARDT K, CHEN L, ISSARD D, KAPPOS L**
Subcutaneous interferon β -1a in the treatment of clinically isolated syndromes: 3- and 5-year results of the Phase III, dosing frequency-blind, multicentre REFLEXION study
J Neurol Neurosurg PS 2016 Dec 30. [Epub ahead of print] IF15: 6.431
17. **COZAC V, EHRENSPERGER M, GSCHWANDTNER U, HATZ F, MEYER A, MONSCH A, SCHUEPBACH, M, TAUB E, FUHR P**
Older candidates for subthalamic deep brain stimulation in Parkinson's disease have a higher incidence of psychiatric serious adverse events
Frontiers in Aging Neuroscience 2016; 8:132 IF: 4.348
18. **COZAC V, CHATURVEDI M, HATZ F, MEYER A, FUHR P, GSCHWANDTNER U**
Increase of EEG spectral theta power indicates higher risk of the development of severe cognitive decline in Parkinson's disease after 3 years
Frontiers in Aging Neuroscience 2016; 8:284 IF: 4.348
19. **CRICK PJ, GRIFFITHS WJ, ZHANG J, BEIBEL M, ABDEL-KHALIK J, KUHLE J, SAILER AW, WANG Y**
Reduced Plasma Levels of 25-Hydroxycholesterol and Increased Cerebrospinal Fluid Levels of Bile Acid Precursors in Multiple Sclerosis Patients
Mol Neurobiol 2016 Nov 23. [Epub ahead of print] IF: 5.397
20. **DAH DAL P, MEYER A, CHATURVEDI M, NOWAK K, ROESCH A, FUHR P, GSCHWANDTNER U**
Fine motor function skills in patients with Parkinson disease (PD) with and without mild cognitive impairment (MCI)
Dementia and geriatric cognitive disorders 2016; 42:127-134 IF: 3.408
21. **DATTA E, PAPINUTTO N, SCHLAEGER R, ZHU A, CARBALLIDO-GAMIO J, HENRY RG**
Gray matter segmentation of the spinal cord with active contours in MR images
Neuroimage 2016 Aug 2. [Epub ahead of print] IF 5.463
22. **DE MARCHIS GM, PUGIN D, MEYERS E, VELASQUEZ A, SUWATCHARANGKOON S, PARK S, FALO MC, AGARWAL S, MAYER S, SCHMIDT JM, CONNOLLY ES, CLAASSEN J**
Seizure burden in subarachnoid hemorrhage associated with functional and cognitive outcome
Neurology 2016; 86:253-60. IF: 8.166
23. **DENGLER NF, MADAI VI, WUERFEL J, VON SAMSON-HIMMELSTJERNA FC, DUSEK P, NIENDORF T, SOBESKY J, VAJKOCZY P**
Moyamoya vessel pathology imaged by ultra-high-field magnetic resonance imaging at 7.0 T
J Stroke Cerebrovasc Dis 2016; 25(6):1544-51. IF: 1.669
24. **DERFUSS T, ONTANEDA D, NICHOLAS J, MENG X, HAWKER K.**
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials
Mult Scler Relat Disord 2016; 8:124-30. IF 1.150
25. **DIMELOE S, MEHLING M, FRICK C, LOELIGER J, BANTUG GR, SAUDER U, FISCHER M, BELLE R, DEVELIOGLU L, TAY S, LANGENKAMP A, HESS C**
The Immune-Metabolic Basis of Effector Memory CD4+ T Cell Function under Hypoxic Conditions
J Immunol 2016;196(1):106-14. IF 4.985
26. **DISANTO G, BENKERT P, LORSCHIEDER J, MUELLER S, VEHOFF J, ZECCA C, RAMSEIER S, ACHTNIHTS L, FINDLING O, NEDELTCHEV K, RADUE EW, SPRENGER T, STIPPICH C, DERFUSS T, LOUVION JF, KAMM C, MATTLE H, LOTTER C, DU PASQUIER R, SCHLUEP M, POT C, LALIVE PH, YALDIZLI Ö, GOBBI C, KAPPOS L, KUHLE J** for the SMSC Scientific Board
The Swiss Multiple Sclerosis Cohort-Study (SMSC): a prospective Swiss wide investigation of key phases in disease evolution and new treatment options
PLoS One 2016; 11(3):e0152347. IF: 3.057
27. **DISANTO G, ADIUTORI R, DOBSON R, MARTINELLI V, DALLA COSTA G, RUNIA T, EVDOSHENKO E, THOUVENOT E, TROJANO M, NORGREN N, TEUNISSEN C, KAPPOS L, GIOVANNONI G, KUHLE J,** International Clinically Isolated Syndrome Study Group
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
J Neurol Neurosurg Psychiatry 2016; 87(2):126-9. IF: 6.431
28. **DITTRICH T, TSCHUDIN-SUTTER S, WIDMER AF, RÜEGG S, MARSCH S, SUTTER R**
Risk factors for new-onset delirium in patients with bloodstream infections: independent and quantitative effect of catheters and drainages – a four-year cohort study
Ann Intensive Care 2016; 6(1):104. IF: 4.529
29. **DOIG D, TURNER EL, DOBSON J, FEATHERSTONE RL, LO RT, GAINES PA, MACDONALD S, BONATI LH, CLIFTON A, BROWN MM, ICSS INVESTIGATORS**
Predictors of Stroke, Myocardial Infarction or Death within 30 Days of Carotid Artery Stenting: Results from the International Carotid Stenting Study

30. DOIG D, HOBSON BM, **MULLER M**, JAGER HR, FEATHERSTONE RL, BROWN MM, **BONATI LH**, RICHARDS T AND THE ICSS-MRI STUDY INVESTIGATORS
Carotid Anatomy Does Not Predict the Risk of New Ischaemic Brain Lesions on Diffusion-Weighted Imaging after Carotid Artery Stenting in the ICSS-MRI Substudy
Eur J Vasc Endovasc Surg 2016; 51:14-20. IF: 2.912
31. **D'SOUZA M**, **YALDIZLI Ö**, JOHN R, VOGT DR, **PAPADOPOULOU A**, LUCASSEN E, MENEGOLA M, ANDELOVA M, DAHLKE F, SCHNYDER F, **KAPPOS L**
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study
Mult Scler J 2016 Jul. [Epub ahead of print] IF: 4.671
32. DUSEK P, BAHN E, LITWIN T, JABŁONKA-SALACH K, ŁUCIUK A, HUELNHAGEN T, MADAI VI, DIERINGER MA, BULSKA E, KNAUTH M, NIENDORF T, SOBESKY J, PAUL F, SCHNEIDER SA, CZLONKOWSKA A, BRÜCK W, WEGNER C, **WUERFEL J**
Brain iron accumulation in wilson disease: a post mortem 7 Tesla MRI - histopathological study
Neuropathol Appl Neurobiol 2016 Aug 20. [Epub ahead of print] IF: 4.483
33. FEATHERSTONE RL, DOBSON J, EDERLE J, DOIG D, **BONATI LH**, MORRIS S, PATEL NV, BROWN MM
Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): a randomised controlled trial with cost-effectiveness analysis
Health Technol Assess 2016; 20:1-94. IF: 4.058
34. FILIPPI M, ROCCA MA, CICCARELLI O, DE STEFANO N, EVANGELOU N, **KAPPOS L**, ROVIRA, A, SASTRE-GARRIGA J, TINTORÉ M, FREDERIKSEN JL, GASPERINI C, PALACE J, REICH DS, BANWELL B, MONTALBAN X, BARKHOF F; MAGNIMS Study Group
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
Lancet Neurol 2016; 15(3):292-303. IF: 23.468
35. **FISCHER D**, HAFNER P, RUBINO D, SCHMID M, NEUHAUS C, JUNG H, BIERI O, HAAS T, GLOOR M, FISCHMANN A, BONATI U
The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study
Neuromuscul Disord 2016; 26(7):414-22. IF: 3.107
36. FOX J, KRAEMER M, SCHORMANN T, DABRINGHAUS A, HIRSCH J, EISELE P, SZABO K, **AMANN M**, **WEIER K**, **NAEGELIN Y**, **KAPPOS L**, GASS A
Individual assessment of brain tissue changes in MS. The effect of focal lesions on short term focal atrophy development in MS. A Voxel-guided morphometry study
Nt J Mol Sci 2016; 17(4):489. IF15: 3.257
37. **GENSICKE H**, STRBIAN D, ZINKSTOK SM, SCHEITZ JF, BILL O, HAMETNER C, MOULIN S, ZINI A, KAGI G, PEZZINI A, PADJEN V, BEJOT Y, CORBIERE S, ZONNEVELD TP, **SEIFFGE DJ**, ROOS YB, **TRAENKA C**, PUTAALA J, **PETERS N**, **BONATI LH**, CURTZE S, ERDUR H, SIBOLT G, KOCH P, VANDELLI L, RINGLEB P, LEYS D, CORDONNIER C, MICHEL P, NOLTE CH, **LYRER PA**, TATLISUMAK T, NEDERKOORN PJ, **ENGELTER ST**
Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before Stroke
Stroke. 2016; 47(2):450-6. IF: 5.787
38. **GENSICKE H**, WICHT A, BILL O, ZINI A, COSTA P, KAGI G, STARK R, **SEIFFGE DJ**, **TRAENKA C**, **PETERS N**, **BONATI LH**, GIOVANNINI G, **DE MARCHIS GM**, POLI L, **POLYMERIS A**, VANACKER P, SARIKAYA H, **LYRER PA**, PEZZINI A, VANDELLI L, MICHEL P, **ENGELTER ST**, THROMBOLYSIS IN STROKE PATIENTS (TRISP) COLLABORATORS
Impact of body mass index on outcome in stroke patients treated with intravenous thrombolysis
Eur J Neurol 2016; 23(12):1705-1712. IF: 3.956
39. GIOVANNONI G, **KAPPOS L**, GOLD R, KHATRI BO, SELMAJ K, UMANS K, GREENBERG S, SWEETSER M, ELKINS J, MCCROSKERY P
Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
Mult Scler Relat Disord 2016; (9):36-46 IF15: 1.150
40. GOLD R, ARNOLD DL, BAR-OR A, HUTCHINSON M, **KAPPOS L**, HAVRDOVA E, MACMANUS D, YOUSRY TA, POZZILLI C, SELMAJ K, SWEETSER MT, ZHANG R, YANG M, POTTS J, NOVAS M, MILLER DH, KURUKULASURIYA NC, FOX RJ, PHILLIPS JT
Long-term effects of delayed-release Dimethyl Fumarate in Multiple Sclerosis: Interim analysis of ENDORSE, a randomized extension study
Mult Scler J 2016 May. [Epub ahead of print] IF15: 4.671
41. GRIMM A, VITTORE D, SCHUBERT V, **RASENACK M**, **DÉCARD BF**, HEILING B, HAMMER N, AXER H
Ultrasound aspects in therapy-naïve CIDP compared to long-term treated CIDP
J Neurol 2016; 263(6):1074-82 IF: 3.408
42. GRIMM A, VITTORE D, SCHUBERT V, LIPSKI C, HEILING B, **DECARD BF**, AXER H
Ultrasound pattern sum score, homogeneity score and regional nerve enlargement index for differentiation of demyelinating inflammatory and hereditary neuropathies
Clin Neurophysiol 2016; 127(7):2618-24. IF 3.426
43. GRIMM A, **DECARD BF**, SCHRAMM A, **PRÖBSTEL AK**, **RASENACK M**, AXER H, **FUHR P**
Ultrasound and electrophysiologic findings in patients with Guillain-Barré syndrome at disease onset and over a period of six months
Clin Neurophysiol 2016; 127:1657-1663. IF: 3.426
44. GRIMM A, **RASENACK M**, **ATHANASOPOULOU IM**, DAMMEIER N, LIPSKI C, WOLKING S, VITTORE D, **DECARD BF**, AXER H

The modified ultrasound pattern sum score mUPSS as additional diagnostic tool for genetically distinct hereditary neuropathies
J Neurol 2016; 263(2):221-30. IF: 3.408

45. GSCHWINDA M, **HARDMEIER M**, VAN DE VILLE D, TOMBESCU M, PENNER I, **NAEGELIN Y**, **FUHR P**, MICHEL C, SEECK M
Fluctuations of spontaneous EEG topographies predict disease state in relapsing-remitting multiple sclerosis
Neuroimage 2016; 12:466–477. IF: 5.463
46. HADINIA A, **MEYER A**, **NOWAK K**, NYBERG E, **FUHR P**, STIEGLITZ RD, **GSCHWANDTNER U**
Kognitive Verhaltenstherapie von Angst und Depression bei Patienten mit Morbus Parkinson
Fortschritte der Neurologie und Psychiatrie 2016; 84:336-343 IF: 0.803
47. HAFNER P, BONATI U, **ERNE B**, SCHMID M, RUBINO D, POHLMAN U, PETERS T, RUTZ E, FRANK S, NEUHAUS C, DEUSTER S, GLOOR M, BIERI O, FISCHMANN A, **SINNREICH M**, GUEVEN N, **FISCHER D**
Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study
PLoS One 2016; 11(1):e0147634. IF: 3.057
48. HAFNER P, BONATI U, RUBINO D, GOICHEVA V, ZUMBRUNN T, GUEVEN N, **FISCHER D**
Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial
Trials 2016; 17(1):389. IF: 1.859
49. **HATZ F**, **HARDMEIER M**, **BOUSLEIMAN H**, **RÜEGG S**, SCHINDLER C, **FUHR P**
Reliability of Functional Connectivity of Electroencephalography Applying Microstate-Segmented Versus Classical Calculation of Phase Lag Index
Brain Connectivity 2016; 6:461-469 IF: 3.83
50. HEGEN H, ADRIANTO I, LESSARD CJ, MILLONIG A, BERTOLOTTA A, COMABELLA M, GIOVANNONI G, GUGER M, HOELZL M, KHALIL M, FAZEKAS F, KILLESTEIN J, LINDBERG RL, MALUCCHI S, **MEHLING M**, MONTALBAN X, RUDZKI D, SCHAUTZER F, SELLEBJERG F, SORENSEN PS, DEISENHAMMER F, STEINMAN L, AXTELL RC
Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients
Neurol Neuroimmunol Neuroinflamm 2016;3(2):e202. IF: -
51. **HERRENDORFF R**, FALESCHINI MT, **STIEFVATER A**, **ERNE B**, **WIKTOROWICZ T**, KERN F, HAMBURGER M, POTTERAT O, **KINTER J**, **SINNREICH M**
Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I
J Biol Chem 2016; 291(33):17165-77. IF: 4.258
52. **HÖRSTER H**, GARTHE A, WALKER TL, ICHWAN M, STEINER B, KHAN MA, LIE DC, NICOLA Z, RAMIREZ-RODRIGUEZ G, KEMPERMANN G
p27kip1 is required for functionally relevant adult hippocampal neurogenesis in mice
Stem Cells 2016 Oct 28. [Epub ahead of print] IF: 5.902
53. HOWARD G, ROUBIN GS, JANSEN O, HENDRIKSE J, HALLIDAY A, FRAEDRICH G, ECKSTEIN HH, CALVET D, BULBULIA R, **BONATI LH**, BECQUEMIN JP, ALGRA A, BROWN MM, RINGLEB PA, BROTT TG, MAS JL AND THE CAROTID STENTING TRIALISTS COLLABORATION
Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials
Lancet 2016; 387:1305-11. IF: 44.002
54. ISOBE N, KESHAVAN A, GOURRAUD PA, ZHU AH, DATTA E, **SCHLAEGER R**, CAILLIER SJ, SANTANIELLO A, LIZÉE A, HIMMELSTEIN DS, BARANZINI SE, HOLLENBACH J, CREE BA, HAUSER SL, OKSENBERG JR, HENRY RG
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis
JAMA Neurol 2016; 73(7):795-802. IF 8.230
55. JOHNSTON SC, AMARENCO P, ALBERS GW, DENISON H, EASTON JD, EVANS SR, HELD P, JONASSON J, MINEMATSU K, MOLINA CA, WANG Y, WONG KS, COMMITTEE SS and INVESTIGATORS* (***LYRER PA**)
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
N Engl J Med 2016; 375:35-43. IF: 59.558
56. JOKUBAITIS VG, SPELMAN T, KALINCIK T, **LORSCHIEDER J**, HAVRDOVA E, HORAKOVA D, DUQUETTE P, GIRARD M, PRAT A, IZQUIERDO G, GRAMMOND P, VAN PESCH V, PUCCI E, GRAND'MAISON F, HUPPERTS R, GRANELLA F, SOLA P, BERGAMASCHI R, IULIANO G, SPITALERI D, BOZ C, HODGKINSON S, OLASCOAGA J, VERHEUL F, MCCOMBE P, PETERSEN T, ROZSA C, LECHNER-SCOTT J, SALADINO ML, FARINA D, IAFFALDANO P, PAOLICELLI D, BUTZKUEVEN H, LUGARESIA, TROJANO M; MSBase Study Group
Predictors of long-term disability accrual in relapse-onset multiple sclerosis
Ann Neurol 2016; 80(1):89-100 IF: 9.638
57. KAHLES T, MONO ML, HELDNER MR, BAUMGARTNER RW, SARIKAYA H, LUFT A, BOHLHALTER S, **TRAENKA C**, **ENGELTER ST**, KURKA N, KOHRMANN M, CURTZE S, MICHEL P, TATLISUMAK T, NEDELTCHEV K
Repeated Intravenous Thrombolysis for Early Recurrent Stroke: Challenging the Exclusion Criterion
Stroke 2016; 47:2133-5. IF: 5.787
58. KALINCIK T, **KUHLE J**, PUCCI E, ROJAS JI, TSOLAKI M, SIRBU CA, SLEE M, BUTZKUEVEN H, MSBase Scientific Leadership Group and MSBase Study Group
Data quality evaluation for observational multiple sclerosis registries
Mult Scler J 2016 Aug 1. [Epub ahead of print] IF: 4.671
59. **KAPPOS L**, ARNOLD DL, BAR-OR A, CAMM J, **DERFUSS T**, KIESEIER BC, **SPRENGER T**, GREENOUGH K, NI P, HARADA T

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
Lancet Neurol 2016; 15(11):1148-59. IF 23.468

60. **KAPPOS L, RADUE EW, CHIN P, RITTER S, TOMIC D, LUBLIN F**
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis
J Neurol 2016; 263: 354-60 IF: 3.408
61. **KAPPOS L, EDAN G, FREEDMAN MS, MONTALBÁN X, HARTUNG HP, HEMMER B, FOX EJ, BARKHOF F, SCHIPLING S, SCHULZE A, PLEIMÉS D, POHL C†, SANDBRINK R, SUAREZ G, WICKLEIN EM, for the BENEFIT Study Group**
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Neurology 2016; 87(10):978-87 IF: 8.166
62. **KAPPOS L, LI D, STUEVE O, HARTUNG HP, FREEDMAN MS, HEMMER B, RIECKMANN P, MONTALBAN X, ZIEMSEN T, HUNTER B, ARNOULD S, WALLSTRÖM E, SELMAJ K**
Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: the dose-blinded, randomized extension phase of the phase 2 BOLD study
JAMA Neurol 2016; 73(9):1089-98 IF: 8.230
63. **KAPPOS L, DE STEFANO N, FREEDMAN MS, CREE BAC, RADUE EW, SPRENGER T, SORMANI MP, SMITH T, HÄRING DA, PIANI MEIER D, TOMIC D**
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis
Mult Scler J 2016; 22(10):1297-305 IF: 4.671
64. **KAPPOS L, HAVRDOVA E, GIOVANNONI G, KHATRI B, GAUTHIER S, GREENBERG S, YOU P, WANG P, GIANNATTASIO G**
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study
Mult Scler J 2016 Dec [Epub ahead of print] IF15: 4.671
65. **KELLERT L, KLOSS M, PEZZINI A, DEBETTE S, LEYS D, CASO V, THIJS VN, BERSANO A, TOUZE E, TATLISUMAK T, TRAENKA C, LYRER PA, ENGELTER ST, METSO TM, GROND-GINSBACH C, CERVICAL ARTERY DISSECTION AND ISCHEMIC STROKE PATIENTS (CADISP) STUDY GROUP**
Prognostic significance of pulsatile tinnitus in cervical artery dissection
Eur J Neurol 2016; 23:1183-7. IF: 3.956
66. **KELLY PJ, ALBERS GW, CHATZIKONSTANTINOVA A, DE MARCHIS GM, FERRARI J, GEORGE P, KATAN M, KNOFLACH M, KIM JS, LI L, LEE EJ, OLIVOT JM, PURROY F, RAPOSO N, ROTHWELL PM, SHARMA VK, SONG B, TSVIGOULIS G, WALSH C, XU Y, MERWICK A**
Validation and comparison of imaging-based scores for prediction of early stroke risk after transient ischaemic attack: a pooled analysis of individual-patient data from cohort studies
Lancet Neurol 2016; 15:1238-47. IF: 23.468
67. **KESHAVAN A, PAUL F, BEYER MK, ZHU AH, PAPANUTTO N, SHINOHARA RT, STERN W, AMANN M, BAKSHI R, BISCHOF A, CARRIERO A, COMABELLA M, CRANE JC, D'ALFONSO S, DEMAEREL P, DUBOIS B, FILIPPI M, FLEISCHER V, FONTAINE B, GAETANO L, GORIS A, GRAETZ C, GRÖGER A, GROPPA S, HAFLER DA, HARBO HF, HEMMER B, JORDAN K, KAPPOS L, KIRKISH G, LLUFRIU S, MAGON S, MARTINELLI-BONESCHI F, MCCAULEY J, MONTALBAN X, MUHLAU M, PELLETIER D, PATTANY PM, PERICAK-VANCE M, REBEIX I, ROCCA M, ROVIRA A, SCHLAEGER R, SAIZ A, SPRENGER T, STECCO A, UITDEHAAG BM, VILLOSLADA P, WATTJES MP, WEINER H, WUERFEL J, ZIMMER C, ZIPP F, INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM, HAUSER S, OKSENBERG JR, HENRY RG**
Power estimation for non-standardized multisite studies
Neuroimage 2016; 134: 281-94 IF: 5.463
68. **KUHLE J, HARDMEIER M, DISANTO G, GUGLETA K, ECSEDI M, LIENERT C, AMATO MP, BAUM K, BUTTMANN M, BAYAS A, BRASSAT D, BROCHET B, CONFAVREUX C, EDAN G, FÄRKKILÄ M, FREDRIKSON S, FRONTONI M, D'HOOGE M, HUTCHINSON M, DE KEYSER J, KIESEIER BC, KÜMPFEL T, RIO J, POLMAN C, ROULLET E, STOLZ C, VASS K, WANDINGER KP, KAPPOS L; European Long-term Follow-up Study Group in Interferon β -1b in Secondary-progressive Multiple Sclerosis.**
A 10-year follow-up of the European multicenter trial of interferon β -1b in secondary-progressive multiple sclerosis
Mult Scler J 2016; 22(4):533-43. IF: 4.671
69. **KUHLE J, BARRO C, ANDREASSON U, DERFUSS T, LINDBERG R, SANDELIUS Å, LIMAN V, NORGREN N, BLENNOW K, ZETTERBERG H**
Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
Clin Chem Lab Med 2016; 54(10):1655-61. IF 3.017
70. **KUHLE J, BARRO C, DISANTO G, MATHIAS A, SONESON C, BONNIER G, YALDIZLI Ö, REGENITER A, DERFUSS T, CANALES M, SCHLUEP M, DU PASQUIER R, KRUEGER G, GRANZIERA C**
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity
Mult Scler J 2016; 22(12):1550-1559. IF 4.671
71. **LIMBERG M, DISANTO G, BARRO C, KUHLE J**
Neurofilament light chain determination from peripheral blood samples
Meth Mol Biol 2016; 1304:93-8. 2016. IF: 1.17
72. **LORSCHIEDER J, BUZZARD K, JOKUBAITIS V, SPELMAN T, HAVRDOVA E, HORAKOVA D, TROJANO M, IZQUIERDO G, GIRARD M, DUQUETTE P, PRAT A, LUGARESIA A, GRAND'MAISON F, GRAMMOND P, HUPPERTS R, ALROUGHANI R, SOLA P, BOZ C, PUCCI E, LECHNER-SCOTT J, BERGAMASCHI R, OREJA-GUEVARA C, IULIANO G, VAN PESCH V, GRANELLA F, RAMO-TELLO C, SPITALERI D, PETERSEN T, SLEE M, VERHEUL F, AMPAPA R, AMATO MP, MCCOMBE P, VUCIC S, SÁNCHEZ**

MENOYO JL, CRISTIANO E, BARNETT MH, HODGKINSON S, OLASCOAGA J, SALADINO ML, GRAY O, SHAW C, MOORE F, BUTZKUEVEN H, KALINCIK T; MSBase Study Group
Defining secondary progressive multiple sclerosis
Brain 2016; 139(Pt 9): 2395-405. IF: 10.103

73. LU CH, ALLEN K, OEI F, LEONI E, **KUHLE J**, TREE T, FRATTA P, SHARMA N, SIDLE K, HOWARD R, ORRELL R, FISH M, GREENSMITH L, PEARCE N, GALLO V, MALASPINA A
Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis
Neurol Neuroimmunol Neuroinflamm 2016; 3(4):e244. IF: -
74. LUBLIN F, MILLER DH, FREEDMAN M, CREE B, WOLINSKY J, WEINER H, LUBETZKI C, HARTUNG H-P, MONTALBAN X, UITDEHAAG BMJ, MERSCHHEMKE M, LI B, PUTZKI N, LIU F, HAERING DA, **KAPPOS L** on behalf of the INFORMS study investigators
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Lancet 2016; 387(10023):1075-84 IF: 44.002
75. MARRIE RA, MILLER A, SORMANI MP, THOMPSON A, WAUBANT E, TROJANO M, O'CONNOR P, FIEST K, REIDER N, REINGOLD S, COHEN JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis (including **DERFUSS T**)
Recommendations for observational studies of comorbidity in multiple sclerosis
Neurology 2016; 86(15):1446-53. IF 8.166
76. MARRIE RA, MILLER A, SORMANI MP, THOMPSON A, WAUBANT E, TROJANO M, O'CONNOR P, REINGOLD S, COHEN JA; attendees of the International Workshop on Comorbidity in Multiple Sclerosis (including **DERFUSS T**)
The challenge of comorbidity in clinical trials for multiple sclerosis
Neurology 2016; 86(15):1437-45. IF 8.166
77. MAURER M, COMI G, FREEDMAN MS, **KAPPOS L**, OLSSON TP, WOLINSKY JS, MILLER AE, DIVE-POULETTY C, BOZZI S, O'CONNOR PW
Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life – a post hoc analysis of the TEMSO and TOWER studies
Mult Scler Relat Disord 2016; 7: 33-40 IF15: 1.150
78. McLENNAN SR, **DIEBOLD M**, RICH LE, ELGER BS
Nurses' perspectives regarding the disclosure of errors to patients: A qualitative study
Int J Nurs Stud 2016; 54:16-22. IF: 3.561
79. MEETER LH, DOPPER EG, JISKOOT LC, SANCHEZ-VALLE R, GRAFF C, BENUSSI L, GHIDONI R, PIJNENBURG YA, BORRONI B, GALIMBERTI D, LAFORCE RJ, MASELLI M, VANDENBERGHE R, BER IL, OTTO M, VAN MINKELN R, PAPMA JM, ROMBOUTS SA, BALASA M, ÖJERSTEDT L, JELIC V, DICK KM, CASH DM, HARDING SR, JORGE CARDOSO M, OURSELIN S, ROSSOR MN, PADOVANI A, SCARPINI E, FENOGLIO C, TARTAGLIA MC, LAMARI F, **BARRO C**, **KUHLE J**, ROHRER JD, TEUNISSEN CE, VAN SWIETEN JC
Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Ann Clin Transl Neurol 2016; 3(8): 623-36. IF: -
80. **MEIRA M**, **SIEVERS C**, **HOFFMANN F**, HAGHIKIA A, **RASENACK M**, **DECARD BF**, **KUHLE J**, **DERFUSS T**, **KAPPOS L**, **LINDBERG RL**
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Neurol Neuroimmunol Neuroinflamm 2016; 3(3):e223. IF: -
81. **MEYER A**, HADINIA A, **HATZ F**, MARTINEZ-MARTIN P, **FUHR P**, STIEGLITZ RD, **GSCHWANDTNER U**
Deutsche Übersetzung und Validierung der Checkliste zur Erfassung neuropsychiatrischer Störungen bei Parkinsonerkrankung (CENS-PE) / German Translation and Validation of the Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's disease (SEND-PD).
Fortschritte der Neurologie & Psychiatrie 2016; 84:421-427 IF: 0.803
82. O'CONNOR P, COMI G, FREEDMAN MS, MILLER AE, **KAPPOS L**, BOUCHARD JP, LEBRUN-FRENAY C, MARES J, BENAMOR M, THANGAVELU K, LIANG J, TRUFFINET P, LAWSON VJ, WOLINSKY JS for the Teriflunomide Multiple Sclerosis Oral (TEMSO) trial group and the MRI-AC
Long-term safety and efficacy of teriflunomide: Nine year follow-up of the randomized TEMSO study
Neurology 2016; 86(10):920-30 IF: 8.166
83. **OZCELIK S**, **SPRENGER F**, SKACHOKOVA Z, FRASER G, ABRAMOWSKI D, CLAVAGUERA F, PROBST A, FRANK S, MÜLLER M, STAUFENBIEL M, GOEDERT M, TOLNAY M, **WINKLER DT**
Co-expression of truncated and full-length tau induces severe neurotoxicity
Molecular Psychiatry 2016; 21(12):1790-1798. IF 13.314
84. PACHE F, ZIMMERMANN H, FINKE C, LACHETA A, PAPAZOGLU S, KUCHLING J, **WUERFEL J**, HAMM B, RUPRECHT K, PAUL F, BRANDT AU, SCHEEL M
Brain parenchymal damage in neuromyelitis optica spectrum disorder - A multimodal MRI study
Eur Radiol 2016;26(12):4413-4422. IF: 3.640
85. PARDINI M, BOTZKOWSKI D, MÜLLER S, VEHOFF J, **KUHLE J**, RUBERTE E, **WUERFEL J**, GASS A, VALMAGGIA C, TETTENBORN B, PUTZKI N, **YALDIZLI Ö**
The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography
Eur J Neurol 2016; 23(12):1769-1774. IF: 3.956
86. PARDINI M, SUDRE CH, PRADOS F, **YALDIZLI Ö**, SETHI V, MUHLERT N, SAMSON RS, VAN DE PAVERT SH, CARDOSO MJ, OURSELIN S, GANDINI WHEELER-KINGSHOTT CA, MILLER DH, CHARD DT
Relationship of grey and white matter abnormalities with distance from the surface of the brain in multiple sclerosis

J Neurol Neurosurg Psychiatry 2016; 87(11):1212-1217. IF: 6.431

87. **PARDINI M, CORDANO C, GUIDA S, GRAFMAN J, KRUEGER F, SASSOS D, MASSUCCO D, ABATE L, YALDIZLI Ö, SERRATI C, AMORE M, MATTEI C, COCITO L, EMBERTI GIALLORETI L**
Prevalence and cognitive underpinnings of isolated apathy in young healthy subjects
J Affect Disord 2016; 189:272-5. IF: 3.383
88. **PEZOLD S, HORVATH A, FUNDANA K, TSAGKAS CH, ANDELOVA M, WEIER K, AMANN M, CATTIN PC**
Automatic, Robust, and Globally Optimal Segmentation of Tubular Structures
In Ourselin S., Joskowicz L., Sabuncu M., Unal G., Wells W. (eds) Medical Image Computing and Computer-Assisted Intervention -- MICCAI 2016. Lecture Notes in Computer Science, vol 9902. Springer, Cham: 362-370. IF: -
89. **POLYMERIS A, TRAENKA C, HERT L, SEIFFGE DJ, PETERS N, DE MARCHIS GM, BONATI LH, LYRER PA, ENGELTER ST**
Frequency and Determinants of Adherence to Oral Anticoagulants in Stroke Patients with Atrial Fibrillation in Clinical Practice
Eur Neurol. 2016; 76:187-93. IF: 1.403
90. **POLYMERIS AA, TESSA A, ANAGNOSTOPOULOU K, RUBEGNI A, GALATOLO D, DINOPOULOS A, GIKA AD, YOUROUKOS S, SKOUTELI E, SANTORELLI FM, PONS R**
A series of Greek children with pure hereditary spastic paraplegia: clinical features and genetic findings
J Neurol 2016; 263:1604-11. IF: 3.408
91. **PRAVATÀ E, ZECCA C, SESTIERI C, CAULO M, RICCITELLI GC, ROCCA MA, FILIPPI M, CIANFONI A, GOBBI C**
Hyperconnectivity of the dorsolateral prefrontal cortex following mental effort in multiple sclerosis patients with cognitive fatigue
Mult Scler J 2016; 22(13):1665-1675. IF: 4.671
92. **PRÖBSTEL AK, KUHLE J, LECOURT AC, VOCK I, SANDERSON NSR, KAPPOS L, DERFUSS T**
Multiple Sclerosis and Antibodies against KIR4.1
New Engl J Med 2016; 374(15):1496-8 IF: 59.558
93. **PRÖBSTEL AK, SCHALLER A, LIEB J, HENCH J, FRANK S, FUHR P, KAPPOS L, SINNREICH M**
Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic
Neurol Genet. 2016; 2(6):e121. IF: -
94. **RAMYEAD A, STUDERUS E, KOMETER M, UTTINGER M, GSCHWANDTNER U, FUHR P, RIECHER-RÖSSLER A**
Prediction of psychosis using neural oscillations and machine learning in neuroleptic-naïve at-risk patients
World J Biol Psychiatry 2016; 17:285-295 IF: 4.159
95. **RASCHE L, HEISERICH L, BEHRENS JR, LENZ K, PFUHL C, WAKONIG K, GIEß RM, FREITAG E, EBERLE C, WUERFEL J, DÖRR J, BAUER P, BELLMANN-STROBL J, PAUL F, ROGGENBUCK D, RUPRECHT K**
Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study
PLoS One 2016;11(1):e0147968. IF: 3.057
96. **RASENACK M, RYCHEN J, ANDELOVA M, NAEGELIN Y, STIPPICH C, KAPPOS L, LINDBERG RL, SPRENGER T, DERFUSS T**
Efficacy and Safety of Fingolimod in an Unselected Patient Population
PLoS One. 2016; 11(1):e0146190. IF15: 3.057
97. **RASENACK M, DÉCARD BF, SCHÄDELIN S, GRIMM A, FISCHER D, HAFNER P**
Ultrasonographic reference values for peripheral nerves and nerve roots in the normal population of children and adolescents: study protocol for an observational-prospective trial
BMJ Open 2016; 6(12):e014662. IF: 2.562
98. **RASENACK M, PROEBSTEL AK, ATHANASOPOULOU IM, DECARD BF, GRIMM A**
Nerve Hypertrophy in Primary Amyloidosis
Muscle Nerve 2016; 54(3):510-2. IF 2.713
99. **RASENACK M, DERFUSS T**
Disease activity return after natalizumab cessation in multiple sclerosis
Expert Rev Neurother 2016; 16(5):587-94. IF 2.578
100. **RITZ MF, GROND-GINSBACH C, KLOSS M, TOLNAY M, FLURI F, BONATI LH, TRAENKA C, ZEIS T, SCHAEREN-WIEMERS N, PETERS N, ENGELTER ST, LYRER PA**
Identification of Inflammatory, Metabolic, and Cell Survival Pathways Contributing to Cerebral Small Vessel Disease by Postmortem Gene Expression Microarray
Curr Neurovasc Res 2016; 13:58-67. IF: 2.253
101. **RUST H, KUHLE J, KAPPOS L, DERFUSS T**
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
Neurol Neuroimmunol Neuroinflamm 2016; 3(2):e215. IF: -
102. **RUST H, LUTZ N, HONEGGER F, FISCHER-BARNICOL D, WELGE-LUESSEN A, KAPPOS L, ALLUM JHJ**
Periodic alternating nystagmus in a patient on long-term lithium medication
J Neurol Sci 2016; 15: 252–253. IF: 2.126
103. **SCHIPPLING S, O'CONNOR P, KNAPPERTZ V, POHL C, BOGUMIL T, SUAREZ G, COOK S, FILIPPI M, HARTUNG H-P., COMI G, JEFFREY DR, KAPPOS L, GOODIN DS, ARNASON B**
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial
J Neurol 2016; 263(7): 1418-1426 IF: 3.408
104. **SCHLAEGER R, HARDMEIER M, D'SOUZA M, GRIZE L, SCHINDLER C, KAPPOS L, FUHR P**

Monitoring Multiple Sclerosis by Multimodal Evoked Potentials: numerically versus ordinally scaled scoring systems
Clin Neurophysiol. 2016;127:1864-71 IF: 3.426

105. SCHLEMM L, CHIEN C, BELLMANN-STROBL J, DÖRR J, **WUERFEL J**, BRANDT AU, PAUL F, SCHEEL M
Gadopentetate but not gadobutrol accumulates in the dentate nucleus of multiple sclerosis patients
Mult Scler J 2016 Sep 27. [Epub ahead of print] IF: 4.671
106. SCHUMACHER S, PACHE F, BELLMANN-STROBL J, BEHRENS J, DUSEK P, HARMS L, RUPRECHT K, NYTROVA P, CHAWLA S, NIENDORF T, KISTER I, PAUL F, GE Y, **WUERFEL J**, **SINNECKER T**
Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study
MAGMA 2016; 29:535-541. IF: 2.869
107. SCHWARZ J, BIERBAUM V, MERRIN J, FRANK T, HAUSCHILD R, BOLLENBACH T, TAY S, SIXT M, **MEHLING M**
A microfluidic device for measuring cell migration towards substrate-bound and soluble chemokine gradients
Sci Rep 2016; 6:36440. IF 5.228
108. **SEIFFGE DJ**, **TRAENKA C**, **POLYMERIS A**, **HERT L**, **PETERS N**, **LYRER P**, **ENGELTER ST**, **BONATI LH**, **DE MARCHIS GM**
Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events
Neurology 2016; 87(18):1856-1862. IF: 8.166
109. SEMMLACK S, TSCHUDIN-SUTTER S, WIDMER AF, VALENCA M, **RÜEGG S**, MARSCH S, **SUTTER R**
Independent impact of infections on the course and outcome of status epilepticus: a 10-year cohort study
J Neurol 2016; 263: 1303-1313. IF: 3.408
110. SIMONETTI BG, MONO ML, HUYNH-DO U, MICHEL P, ODIER C, SZTAJZEL R, **LYRER P**, **ENGELTER ST**, **BONATI L**, **GENSICKE H**, **TRAENKA C**, TETTENBORN B, WEDER B, FISCHER U, GALIMANIS A, JUNG S, LUEDI R, **DE MARCHIS GM**, WECK A, CEREDA CW, BAUMGARTNER R, BASSETTI CL, MATTLE HP, NEDELTCHEV K and ARNOLD M
Erratum to: Risk factors, aetiology and outcome of ischaemic stroke in young adults: the Swiss Young Stroke Study
J Neurol 2016; 263:199-200. IF: 3.408
111. **SINNECKER T**, SCHUMACHER S, MUELLER K, PACHE F, DUSEK P, HARMS L, RUPRECHT K, NYTROVA P, CHAWLA S, NIENDORF T, KISTER I, PAUL F, GE Y, **WUERFEL J**
MRI phase changes in multiple sclerosis vs neuromyelitis optica lesions at 7T
Neurol Neuroimmunol Neuroinflamm 2016;3:e259. IF: -
112. **SINNECKER T**, OTHMAN J, KÜHL M, METZ I, NIENDORF T, KUNKEL A, PAUL F, **WUERFEL J**, FAISS J
Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
Case Rep Neurol Med 2016; 2016:5876798. IF: -
113. SORMANI MP, GASPERINI C, ROMEO MAL, RIO J, CALABRESE M, COCCO EE, ENZINGER C, FAZEKAS F, FILIPPI M, GALLO A, **KAPPOS L**, MARROSU MG, MARTINELLI V, PROSPERINI L, ROCCA MA, ROVIRA A, **SPRENGER T**, STROMILLO ML, TEDESCHI G, TINTORE M, TORTORELLA C, TROJANO M, MONTALBAN X, POZZILLI C, COMI G, DE STEFANO N on behalf of the MAGNIMS study group
Assessing response to Interferon-beta in a multicentre dataset of multiple sclerosis patients
Neurology 2016; 87(2):134-140 IF: 8.166
114. SORMANI MP, **KAPPOS L**, RADUE EW, COHEN JA, BARKHOF F, SPRENGER T, PIANI MEIER D, HAERING D, TOMIC D, DE STEFANO N
Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS
Mult Scler J 2016 Jul. [Epub ahead of print] IF15: 4.671
115. SPELMAN T, KALINCIK T, JOKUBAITIS V, ZHANG A, PELLEGRINI F, WIENDL H, BELACHEW S, LUGARES A, HAVRDOVA E, HORAKOVA D, GRAMMOND P, DUQUETTE P, PRAT A, IULIANO G, TERZI M, IZQUIERDO G, HUPPERTS R, BOZ C, PUCCI E, GIULIANI G, SOLA P, SPITALERI D, LECHNER-SCOTT J, BERGAMASCHI R, GRAND'MAISON F, GRANELLA F, **KAPPOS L**, TROJANO M, BUTZKUEVEN H, HYDE R, VERHEUL F
Comparative efficacy of first-line natalizumab versus IFN beta or glatiramer acetate in relapsing Multiple Sclerosis
Neurol Clin Pract 2016; 6(2):102-115 IF: -
116. SPRIGG N, ROBSON K, BATH P, DINEEN R, ROBERTS I, ROBINSON T, ROFFE C, WERRING D, AL-SHAHI SALMAN R, POCOCK S, DULEY L, ENGLAND T, WHYNES D, CICCONE A, LASKA AC, CHRISTENSEN H, OZTURK S, COLLINS R, BERECZKI D, EGEA-GUERRERO JJ, LAW ZK, CZLONKOWSKA A, **SEIFFGE D**, BEREDZIE M and TICH-2 INVESTIGATORS
Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial
Int J Stroke 2016; 11:683-94. IF: 3.044
117. STREITBERGER KJ, FEHLNER A, PACHE F, LACHETA A, PAPAZOGLU S, BELLMANN-STROBL J, RUPRECHT K, BRANDT A, BRAUN J, SACK I, PAUL F, **WUERFEL J**
Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder
Eur Radiol 2016 Aug 29. [Epub ahead of print] IF: 3.640
118. **SUTTER R**, RISTIC A, **RÜEGG S**, **FUHR P**
Myoclonus in the critically ill: Diagnosis, management, and clinical impact
Clin Neurophysiol 2016; 127:67–80 IF: 3.426
119. TRABOULSEE AL, CORNELISSE P, SANDBERG-WOLLHEIM M, UITDEHAAG BMJ, **KAPPOS L**, JONGEN PJ, CONSTANTINESCU CS, VERDUN DI CANTOGNO E, LI DKB
Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis
Multiple Sclerosis Journal – Experimental, Translational and Clinical 2016 Sept 1. [Epub ahead of print] IF: -

120. VAN DALEN YW, BLOKHUIS C, COHEN S, TER STEGE JA, TEUNISSEN CE, **KUHLE J**, KOOTSTRA NA, SCHERPBIER HJ, KUIJPERS TW, REISS P, MAJOIE CB, CAAN MW, PAJKRT D
Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children
Medicine (Baltimore) 2016; 95(12):e3093. IF: 2.133
121. WARRENDER-SPARKES M, SPELMAN T, IZQUIERDO G, TROJANO M, LUGARESÍ A, GRAND'MAISON F, HAVRDOVA E, HORAKOVA D, BOZ C, OREJA-GUEVARA C, ALROUGHANI R, IULIANO G, DUQUETTE P, GIRARD M, TERZI M, HUPPERTS R, GRAMMOND P, PETERSEN T, FERNANDEZ-BOLAÑOS R, FIOLE M, PUCCI E, LECHNER-SCOTT J, VERHEUL F, CRISTIANO E, VAN PESCH V, PETKOVSKA-BOSKOVA T, MOORE F, KISTER I, BERGAMASCHI R, SALADINO ML, SLEE M, BARNETT M, AMATO MP, SHAW C, SHUEY N, YOUNG C, GRAY O, **KAPPOS L**, BUTZKUEVEN H, KALINCIK T, JOKUBAITIS V; MSBASE STUDY GROUP.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Mult Scler J 2016; 22(4):520-32. IF: 4.671
122. **WEIER K**, TILL C, FONOV V, YEH A, ARNOLD D, BANWELL B, COLLINS DL
Contribution of the cerebellum to cognitive function in pediatric multiple sclerosis
Mult Scler J 2016; 22(5):599-607. IF: 4.671
123. **WEIER K**, FONOV V, AUBERT-BROCHE B, ARNOLD D, BANWELL B, COLLINS DL
Impaired growth of the cerebellum in pediatric-onset acquired CNS demyelinating disease
Mult Scler J 2016; 22(10):1266-78. IF: 4.671
124. WEYDT P, OECKL P, HUSS A, MÜLLER K, VOLK AE, **KUHLE J**, KNEHR A, ANDERSEN PM, PRUDLO J, STEINACKER P, WEISHAUPT JH, LUDOLPH AC, OTTO M
Neurofilament levels as biomarkers in asymptomatic and symptomatic familial ALS
Ann Neurol 2016; 79(1): 152-158. IF: 9.638
125. WIENDL H, BUTZKUEVEN H, **KAPPOS L**, TROJANO M, PELLEGRINI F, PAES D, ZHANG A, BELACHEW S on behalf of the TYSABRI® Observational Program (TOP) investigators
Epoch Analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP)
PLoS One. 2016; 11(1): e0144834. IF: 3.057
126. **YALDIZLI Ö**, PENNER IK, YONEKAWA T, **NAEGELIN Y**, **KUHLE J**, PARDINI M, CHARD D, STIPPICH C, KIRA J, **BENDFELDT K**, **AMANN M**, **RADUE EW**, **KAPPOS L**, **SPRENGER T**
The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis
Eur J Neurol 2016; 23(3):510-9. IF: 3.956
127. **YALDIZLI Ö**, PARDINI M, SETHI V, MUHLERT N, LIU Z, TOZER DJ, SAMSON RS, WHEELER-KINGSHOTT CA, YOUSRY TA, MILLER DH, CHARD DT
Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study
Mult Scler J 2016; 22(2):150-9. IF: 4.671
128. **YALDIZLI Ö**, SETHI V, PARDINI M, TUR C, MOK KY, MUHLERT N, LIU Z, SAMSON RS, WHEELER-KINGSHOTT CA, YOUSRY TA, HOULDEN H, HARDY J, MILLER DH, CHARD DT
HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis
Mult Scler Relat Disord 2016;7:47-52. IF: 1.150
129. YAN DER LOGT RP, FINDLING O, **RUST H**, **YALDIZLI Ö**, ALLUM JH
The effect of vibrotactile biofeedback of trunk sway on balance control in multiple sclerosis
Mult Scler Relat Disord 2016; 8:58-63. IF: 1.150
130. WILKE C, PREISCHE O, DEUSCHLE C, ROEBEN B, APEL A, **BARRO C**, MAIA L, MAETZLER W, **KUHLE J***, SYNOFZIK M* (*equal contribution)
Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum
J Neurol Neurosurg Psychiatry 2016; 87(11): 1270-1272. IF: 6.431
131. ZANINI C, MAINO P, MÖLLER JC, **GOBBI C**, RAIMONDI M, RUBINELLI S
Enhancing clinical decisions about care through a pre-consultation sheet that captures patients' views on their health conditions and treatments: A qualitative study in the field of chronic pain
Patient Educ Couns 2016; 99(5):747-53. IF: 2.199
132. ZECCA C, RICCITELLI G, DISANTO G, SINGH A, DIGESU A, PANICARI L, PUCCINI F, MATTIOLI M, TUBARO A, **GOBBI C**
Urinary incontinence in multiple sclerosis: prevalence, severity and impact on patients' quality of life
Eur J Neurol 2016; 23:1228-1234. IF: 4.055
133. ZECCA C, DISANTO G, SORMANI MP, RICCITELLI GC, CIANFONI A, DELGRANDE F, PRAVATÀ E, **GOBBI C**
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis
Mult Scler J 2016; 22(6):782-91. IF: 4.671
134. ZECCA C, PANICARI L, **DISANTO G**, MAINO P, SINGH A, DIGESU GA, **GOBBI C**
Posterior tibial nerve stimulation in the management of lower urinary tract symptoms in patients with multiple sclerosis
Int Urogynecol J 2016; 27(4):521-7. IF: 1.961
135. ZIEMSEN T, GASS A, **WUERFEL J**, BAYAS A, TACKENBERG B, LIMMROTH V, LINKER R, MÄURER M, HAAS J, STANGEL M, MEERGANS M, HARLIN O, HARTUNG HP
Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
BMC Neurol 2016; 16:98. IF: 1.961

B - BUCHBEITRÄGE, ÜBERSICHTSARBEITEN, EDITORIALS & REVIEWS (Alphabetisch nach Erstautor sortiert)

1. AMBLER G, AL-SHAHI SALMAN R, AURIEL E, AY H, BORNSTEIN NM, **ENGELTER S**, FAZEKAS F, FLURI F, GATTRINGER T, GOMEZ-ANSON B, HAYDEN D, HORSTMANN S, JÄGER HR, KELLY P, KWA VIH, LIP GYH, MARTI-FABREGAS J, MICHEL P, MUELLGES W, ORKEN DN, **PETERS N**, PRATS SANCHEZ L, SATO S, **SEIFFGE D**, SHAKESHAFT C, SOO Y, THIJS V, VELTKAMP R, WERRING DJ, WILSON D, WONG LKS, YAKUSHIJI Y
Worldwide collaboration in the Microbleeds International Collaborative Network
Lancet Neurology 2016; 15:1113-1114. IF: 23.468
2. **BONATI LH**, NEDERKOORN PJ
Clinical Perspective of Carotid Plaque Imaging
Neuroimaging Clin N Am 2016; 26:175-82 IF: -
3. **COZAC V**, **GSCHWANDTNER U**, **HATZ F**, **HARDMEIER M**, **RÜEGG S**, **FUHR P**
Quantitative EEG and cognitive decline in Parkinson's disease
Parkinson's Disease 2016; 1-14. IF: 1.722
4. **DECARD BF**, **DERFUSS T**
Promising oral compounds for the treatment of multiple sclerosis - a glance into the future
Semin Neurol 2016; 36(2):128-39. IF 1.838
5. **DIEBOLD M**, **DERFUSS T**
Immunological treatment of multiple sclerosis
Semin Hematol 2016; 53 Suppl 1:S54-7. IF 4.438
6. **DIEBOLD M**, **KAPPOS L**, **DERFUSS T**
Zelldepletion und Myeloablation bei neuroimmunologischen Erkrankungen
Nervenarzt 2016; 87(8):814-20. IF: 0.806
7. **FISCHER D**, **BONATI U**, **WATTJES MP**
Recent developments in muscle imaging of neuromuscular disorders
Curr Opin Neurol 2016; 29(5):614-20. IF: 4.469
8. **FREILINGER T**, **PETERS N**
Migräne und Schlaganfall – eine komplexe wechselseitige Beziehung
Leading Opinions – Neurologie und Psychiatrie 2016;1:10-14. IF: -
9. **HAVLA J**, **WARNKE C**, **DERFUSS T**, **KAPPOS L**, **HARTUNG HP**, **HOHLFELD R**
Interdisziplinäres Risikomanagement in der Therapie der multiplen Sklerose
Deutsches Ärzteblatt 2016; 113(51-52): 879-886 IF15: 3.7
10. **HENCH J**, **ROSHANSKI N**, **HEWER E**, **ROSLER U**, **LASS-FLORL C**, **STIPPICH C**, **TOLNAY M**, **RUSCHE N**, **SONDEREGGER B**, **SAILER M**, **LYRER P**, **PETERS N**, **FRANK S**
Granulomatous encephalitis: protothecosis excluded?
Histopathology 2016; 69(6):1082-1084. IF: 3.425
11. **KUHLE J**
Editorial: Comment: "If you can't measure it, you can't improve it" (Lord Kelvin)
Neurology 2016; 87(13): 1335. IF: 8.166
12. **MELZER N**, **RUCK T**, **FUHR P**, **GOLD R**, **HOHLFELD R**, **MARX A**, **MELMS A**, **TACKENBERG B**, **SCHALKE B**, **SCHNEIDER-GOLD C**, **ZIMPRICH F**, **MEUTH SG**, **WIENDL H**
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.
J Neurol 2016; 263(8):1473-94. IF: 3.408
13. **RÜEGG S**
Epilepsy and aggression
Epileptologie 2016; 33: 55-68. IF: -
14. **SATI P**, **OH J**, **CONSTABLE RT**, **EVANGELOU N**, **GUTTMANN CR**, **HENRY RG**, **KLAWITER EC**, **MAINERO C**, **MASSACESI L**, **MCFARLAND H**, **NELSON F**, **ONTANEDA D**, **RAUSCHER A**, **ROONEY WD**, **SAMARAWEEERA AP**, **SHINOHARA RT**, **SOBEL RA**, **SOLOMON AJ**, **TREABA CA**, **WUERFEL J**, **ZIVADINOV R**, **SICOTTE NL**, **PELLETIER D**, **REICH DS**; **NAIMS COOPERATIVE**
The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative
Nat Rev Neurol 2016; 12(12):714-722. IF: 18.4
15. **SUNDERKÖTTER C**, **NAST A**, **WORM M**, **DENGLER R**, **DÖRNER T**, **GANTER H**, **HOHLFELD R**, **MELMS A**, **MELZER N**, **RÖSLER K**, **SCHMIDT J**, **SINNREICH M**, **WALTER MC**, **WANSCHITZ J**, **WIENDL H**
Guidelines on dermatomyositis--excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology
J Dtsch Dermatol Ges 2016; 14(3):321-38. IF: 2.511
16. **STECK A**, **STECK B**

Reflections on brain and mind
Swiss Arch Neurol Psychiat Psychother 2016;167(5):136-45

17. VENTURA E, MANNO C, **GOBBI C**, VITALE VA, CIANFONI A
MR-Neurography of a vagal neuropathy
Neurology 2016; 87(2):234-5. IF: 8.185
18. ZIEMSEN T, **DERFUSS T**, DE STEFANO N, GIOVANNONI G, PALAVRA F, TOMIC D, VOLLMER T, SCHIPPLING S
Optimizing treatment success in multiple sclerosis
J Neurol 2016; 263(6):1053-65 IF: 3.408